Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 04 tags : Cancer save search
UPMC Hillman Cancer Center
Published: 2021-11-04 (Crawled : 22:00) - kuraoncology.com
KURA | $17.55 -0.74% -0.74% 1.3M
|
Health Technology
|
| O: 0.68%
H: 5.91%
C: 5.1%
cancer
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
Published: 2021-11-04 (Crawled : 21:00) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.43%
H: 0.04%
C: -0.97%
blood therapy cancer
Lantern Pharma Announces Abstract on Effectiveness of LP-284 in Hematologic Cancers Accepted for Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-11-04 (Crawled : 15:15) - biospace.com/
LTRN | $5.42 -6.07% -6.46% 240K
|
Health Technology
|
| O: 0.19%
H: 2.23%
C: -1.15%
presentation ema cancer
AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting
Published: 2021-11-04 (Crawled : 13:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.89%
H: 0.13%
C: -0.43%
IMAB | $1.81 0.56% 0.55% 340K
|
Health Technology
|
| O: 0.56%
H: 2.78%
C: -0.81%
blood cancer research
Beyond Air® Announces Formation of Beyond Cancer™, a New Private Company Dedicated to Oncology Utilizing Ultra-High Concentration Nitric Oxide to Treat Solid Tumors
Published: 2021-11-04 (Crawled : 13:00) - biospace.com/
XAIR | $1.22 2.52% 2.46% 280K
|
Technology Services
|
| O: 19.63%
H: 3.52%
C: -11.56%
solid tumors cancer
Ambrx Biopharma Inc. Announces First Patient Dosed in its Global Phase 2 ACE-Breast-03 Clinical Study of ARX788 for the Treatment of HER2-Positive Metastatic Breast Cancer
Published: 2021-11-04 (Crawled : 13:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
treatment phase 2 biopharma positive cancer breast cancer her2+ her2- her2 metastatic breast cancer
XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer
Published: 2021-11-04 (Crawled : 12:15) - biospace.com/
XOMA | News | $24.97 1.55% 1.52% 17K
|
Health Technology
|
| O: -1.02%
H: 4.27%
C: 0.79%
cancer antibody phase 3 pancreatic pancreas milestone
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.